Palivizumab

Palivizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting Respiratory Syncytial Virus (RSV), for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50. 6 kDa each) and two light chains (27. 6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147. 7 kDa +/- 1 kDa (MALDI-TOF).

Target	Respiratory Syncytial Virus (RSV)
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
CAS Number	188039-54-5
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on Respiratory Syncytial Virus (RSV)

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue